Profile data is unavailable for this security.
About the company
PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
- Revenue in USD (TTM)54.06m
- Net income in USD-93.50m
- Incorporated1986
- Employees75.00
- LocationPDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
- Phone+1 (775) 832-8500
- Fax+1 (775) 832-8501
- Websitehttp://www.pdl.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp | 0.00 | -24.78m | 282.99m | 16.00 | -- | 11.15 | -- | -- | -0.4607 | -0.4607 | 0.00 | 0.4226 | 0.00 | -- | -- | 0.00 | -96.11 | -87.94 | -127.18 | -106.42 | -- | -- | -- | -- | -- | -89.92 | 0.00 | -- | -- | -- | -52.41 | -- | -- | -- |
| Cellular Biomedicine Group Inc | 290.66k | -52.19m | 288.93m | 217.00 | -- | 6.39 | -- | 994.05 | -2.71 | -2.71 | 0.0151 | 2.33 | 0.0028 | -- | 1.12 | 1,339.45 | -50.37 | -49.83 | -61.77 | -54.56 | 81.32 | 23.14 | -17,957.33 | -4,413.84 | -- | -- | 0.2367 | -- | 51.48 | -9.64 | -28.34 | -- | 104.77 | -- |
| Urovant Sciences Ltd | 0.00 | -146.75m | 289.21m | 70.00 | -- | -- | -- | -- | -4.82 | -4.82 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -179.60 | -- | -243.22 | -- | -- | -- | -- | -- | -- | -38.74 | 2.59 | -- | -- | -- | -31.79 | -- | -- | -- |
| Concert Pharmaceuticals Inc | 79.00k | -76.82m | 299.20m | 70.00 | -- | 1.94 | -- | 3,787.36 | -3.07 | -3.07 | 0.0031 | 5.21 | 0.0004 | -- | 13.17 | 1,128.57 | -41.45 | -8.54 | -44.09 | -9.08 | -- | -- | -97,236.71 | -29.27 | -- | -- | 0.00 | -- | -89.75 | -33.96 | -39.52 | -- | -3.15 | -- |
| Rigel Pharmaceuticals, Inc. | 102.43m | -28.05m | 300.05m | 163.00 | -- | 3.82 | -- | 2.93 | -0.1684 | -0.1684 | 0.6106 | 0.4657 | 0.648 | 0.6933 | 13.41 | 628,374.30 | -17.75 | -54.29 | -21.68 | -69.95 | 99.07 | -- | -27.39 | -213.28 | 3.68 | -- | 0.1113 | -- | 33.20 | 48.36 | 5.09 | -- | 28.64 | -- |
| Gritstone Oncology Inc | 4.28m | -102.63m | 301.47m | 176.00 | -- | 2.59 | -- | 70.44 | -2.89 | -2.89 | 0.1206 | 3.12 | 0.0253 | -- | 9.63 | 24,597.70 | -60.64 | -- | -67.09 | -- | -- | -- | -2,397.90 | -- | -- | -- | 0.00 | -- | 267.73 | -- | -45.79 | -- | -- | -- |
| Sutro Biopharma Inc | 41.26m | -61.09m | 308.73m | 177.00 | -- | 2.55 | -- | 7.48 | -2.65 | -2.65 | 1.79 | 3.53 | 0.2316 | -- | 6.65 | 245,589.30 | -34.29 | -- | -41.67 | -- | -- | -- | -148.06 | -- | -- | -85.41 | 0.2274 | -- | 11.24 | -- | -57.84 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 8.55m | -35.43m | 312.85m | 72.00 | -- | 3.81 | -- | 36.61 | -1.97 | -1.97 | 0.4763 | 4.54 | 0.0825 | -- | 13.54 | 118,694.40 | -34.22 | -- | -38.83 | -- | -- | -- | -414.57 | -- | -- | -- | 0.00 | -- | 93.40 | -- | -40.11 | -- | -- | -- |
| Chromadex Corp | 50.59m | -29.71m | 313.54m | 110.00 | -- | 18.37 | -- | 6.20 | -0.5116 | -0.5116 | 0.8697 | 0.2776 | 1.30 | 2.19 | 13.60 | 459,890.90 | -76.64 | -52.15 | -125.05 | -74.63 | 56.89 | 49.87 | -58.73 | -61.88 | 1.24 | -32.23 | 0.0144 | -- | 46.69 | 24.76 | 3.51 | -- | 24.37 | -- |
| PDL BioPharma Inc | 54.06m | -93.50m | 319.62m | 75.00 | -- | 0.6072 | -- | 5.91 | -0.7845 | -0.9035 | 0.4573 | 4.62 | 0.0683 | 4.04 | 3.20 | 720,746.70 | -11.87 | 6.98 | -12.55 | 7.77 | 2.55 | -- | -173.90 | 26.17 | 12.95 | -- | 0.0235 | 31.21 | -72.36 | -37.65 | -2.25 | -- | -50.29 | -- |
| Seres Therapeutics Inc | 35.37m | -65.83m | 327.42m | 108.00 | -- | -- | -- | 9.26 | -1.02 | -1.02 | 0.5526 | -0.8602 | 0.325 | -- | 8.08 | 327,527.80 | -60.49 | -43.81 | -99.75 | -51.66 | -- | -- | -186.09 | -347.19 | -- | -272.42 | -- | -- | 22.07 | -- | 28.97 | -- | 0.02 | -- |
| ANI Pharmaceuticals Inc | 203.43m | -1.46m | 336.04m | 338.00 | -- | 1.64 | 8.74 | 1.65 | -0.144 | -0.144 | 16.90 | 16.63 | 0.4439 | 1.48 | 2.72 | 601,875.80 | -0.298 | 2.94 | -0.4064 | 3.49 | 65.48 | 64.97 | -0.6715 | 6.74 | 1.33 | 1.33 | 0.4985 | 0.00 | 2.47 | 29.84 | -60.91 | -26.83 | 42.73 | -- |
| Aspira Women's Health Inc | 4.96m | -15.23m | 344.72m | 52.00 | -- | 64.96 | -- | 69.57 | -0.1688 | -0.1688 | 0.0539 | 0.0545 | 0.5326 | 42.84 | 6.02 | 95,288.46 | -163.67 | -106.43 | -269.84 | -139.72 | 30.39 | 7.24 | -307.31 | -458.36 | 2.49 | -- | 0.19 | -- | 48.64 | 12.48 | -34.00 | -- | -12.41 | -- |
| Emisphere Technologies, Inc. | 1.04m | -2.15m | 349.90m | 12.00 | -- | -- | -- | 335.15 | -0.0476 | -0.0476 | 0.0166 | -2.55 | 0.1162 | 2.18 | 3.90 | -- | -23.92 | -287.20 | -- | -- | -43.20 | -48.94 | -205.75 | -6,143.77 | 0.7765 | -- | -- | -- | 190.75 | -- | 75.13 | -- | -- | -- |
| MEI Pharma Inc | 4.54m | -24.49m | 351.92m | 40.00 | -- | 4.72 | -- | 77.53 | -0.296 | -0.296 | 0.0551 | 0.7028 | 0.0497 | -- | -- | 113,475.00 | -26.83 | -31.84 | -30.52 | -35.24 | 27.50 | -- | -539.48 | -361.82 | -- | -- | 0.00 | -- | 203.02 | -- | 58.02 | -- | 34.12 | -- |
| Wave Life Sciences Ltd | 17.12m | -196.93m | 354.11m | 301.00 | -- | 16.44 | -- | 20.69 | -5.74 | -5.74 | 0.4987 | 0.8304 | 0.0512 | -- | 3.42 | 56,870.43 | -58.86 | -54.34 | -94.13 | -71.05 | -- | -- | -1,150.43 | -1,455.31 | -- | -- | 0.00 | -- | 10.89 | -- | -32.04 | -- | 46.03 | -- |
Data as of Jul 10 2020. Currency figures normalised to PDL BioPharma Inc's reporting currency: US Dollar USD
49.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 31 Mar 2020 | 9.62m | 8.26% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 9.09m | 7.80% |
| Renaissance Technologies LLCas of 31 Mar 2020 | 8.22m | 7.06% |
| Brandes Investment Partners LPas of 31 Mar 2020 | 5.73m | 4.92% |
| The Vanguard Group, Inc.as of 31 Mar 2020 | 5.37m | 4.61% |
| Silver Point Capital LPas of 31 Mar 2020 | 4.90m | 4.20% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2020 | 4.42m | 3.80% |
| Connor, Clark & Lunn Investment Management Ltd.as of 31 Mar 2020 | 3.74m | 3.21% |
| Citadel Advisors LLCas of 31 Mar 2020 | 3.18m | 2.73% |
| Engine Capital Management LPas of 31 Mar 2020 | 3.16m | 2.71% |
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
